B
Bruno Gagnon
Researcher at Laval University
Publications - 64
Citations - 3467
Bruno Gagnon is an academic researcher from Laval University. The author has contributed to research in topics: Palliative care & Population. The author has an hindex of 23, co-authored 60 publications receiving 3125 citations. Previous affiliations of Bruno Gagnon include University of St. Gallen & McMaster University.
Papers
More filters
Journal ArticleDOI
Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study.
Peter G. Lawlor,Bruno Gagnon,Isabelle Mancini,Jose Pereira,John Hanson,Maria E. Suarez-Almazor,Eduardo Bruera +6 more
TL;DR: Delirium precipitated by opioids and other psychoactive medications and dehydration is frequently reversible with change of opioid or dose reduction, discontinuation of unnecessary psychoactive medication, or hydration, respectively, and patients with delirium had poorer survival rates than controls.
Occurrence, Causes, and Outcome of Delirium in Patients With Advanced Cancer
Peter G. Lawlor,Bruno Gagnon,Isabelle Mancini,Jose Pereira,John Hanson,Maria E. Suarez-Almazor,Eduardo Bruera +6 more
TL;DR: In this paper, the authors found that patients with delirium had poorer survival rates than controls (P.001) when compared to patients with nonreversibility, and psychoactive medications, predominantly opioids, were associated with reversibility.
Journal ArticleDOI
Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia
James R. Wright,Yee C. Ung,Jim A. Julian,Kathleen I. Pritchard,Timothy J. Whelan,Column Smith,Barbara Szechtman,Wilson Roa,Liam Mulroy,Rudinskas L,Bruno Gagnon,Gord S. Okawara,Mark Levine +12 more
TL;DR: An unplanned safety analysis suggested decreased overall survival in patients with advanced NSCLC treated with epoetin alfa, highlighting the need for ongoing trials evaluating erythropoietin receptor agonists to ensure that overall survival is monitored closely.
Journal ArticleDOI
An Eicosapentaenoic Acid Supplement Versus Megestrol Acetate Versus Both for Patients With Cancer-Associated Wasting: A North Central Cancer Treatment Group and National Cancer Institute of Canada Collaborative Effort
Aminah Jatoi,Kendrith M. Rowland,Charles L. Loprinzi,Jeff A. Sloan,Shaker R. Dakhil,Neil MacDonald,Bruno Gagnon,Paul J. Novotny,James A. Mailliard,Teresita I L Bushey,Suresh G. Nair Md,Brad Christensen +11 more
TL;DR: This EPA supplement, either alone or in combination with MA, does not improve weight or appetite better than MA alone and global quality of life was not significantly different among groups.
Journal ArticleDOI
Pandemic palliative care: beyond ventilators and saving lives.
TL;DR: The challenges involved in providing care in the event of a SARS-CoV-2 pandemic are reviewed.